Welcome to the “Golden Age” of PN: Ruxolitinib Cream 1.5% (Opzelura, Incyte) Shows Early Improvement in Itch and Skin Lesions
Twice-daily ruxolitinib cream 1.5% (Opzelura, Incyte) met all primary and key secondary endpoints in a Phase 3 trial of adults with prurigo nodularis (PN). The research was presented as a late-breaker at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, FL. The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate […]